Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.
Status:
Completed
Trial end date:
1997-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety of the buprenorphine transdermal system
(5, 10, and 20 mg) in comparison to placebo transdermal system in subjects with moderate to
severe pain after orthopedic surgery. The double-blind treatment intervention duration is 72
hours during which time supplemental analgesic medication (intravenous morphine PCA) will be
provided to all subjects in addition to study drug.